Clinically acceptable colchicine concentrations have potential for the palliative treatment of XXXX @entity201 .

@entity1 @entity19 @entity5 @entity56811 @entity201
Microtubules are an ideal target for anticancer drugs because of their essential role in mitosis. Colchicine is a microtubule destabilizer. Whether the clinically acceptable colchicine concentrations had anticancer effects on @entity1 @entity201 cells was investigated. Two @entity1 @entity201 cell lines (C14/KMUH, C51/KMUH) were investigated using clinically acceptable plasma colchicine concentrations (2 ng/mL and 6 ng/mL for the in vitro experiment, 0.07 mg colchicine/kg/d * 14 days for the nude @entity19 experiment). Our results showed that colchicine caused significantly dose-dependent antiproliferative effects on both cell lines (all p < 0.0001). Nude @entity19 (BALB/c-nu) experiments showed that the increased @entity5 volume ratios in colchicine-treated @entity19 were significantly lower than control @entity19 started from the 11th day of treatment (p = 0.0167). The @entity5 growth rates in colchicine-treated @entity19 after 14 days of treatment were significantly lower than in control @entity19 (0.147    0.004/d vs. 0.274    0.003/d, p = 0.0015). In addition to the well-known direct colchicine-tubulin interaction as a common anticancer mechanism of colchicine, microarray and quantitative reverse transcriptase-polymerase chain reaction showed that the antiproliferative effects of both 2 ng/mL and 6 ng/mL colchicine on C14/KMUH cells could be partially explained by downregulations of both @entity56811 and MT-COI. There was no effect of colchicine on MT-COI expression in C51/KMUH cells, however, 6 ng/mL colchicine also downregulated @entity56811 in this cell line. In conclusion, clinically acceptable colchicine concentrations can inhibit the proliferation of @entity1 @entity201 cells. This drug has good potential for the palliative treatment of @entity201 due to its low cost and our long-standing prescription experience.
